Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study

@article{Palacios2021EfficacyAS,
  title={Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study},
  author={Ricardo Palacios and Ana Paula Batista and Camila Santos Nascimento Albuquerque and Elizabeth Gonz{\'a}lez Pati{\~n}o and Joane do Prado Santos and M{\^o}nica Tilli Reis Pessoa Conde and Roberta de Oliveira Piorelli and Luiz Carlos Pereira J{\'u}nior and S{\^o}nia Mara Raboni and Fabiano Ramos and Gustavo Adolfo Sierra Romero and Fabio Eudes Leal and Luis Fernando Aranha Camargo and Francisco Hideo Aoki and Eduardo Barbosa Coelho and Danise Senna Oliveira and Cor Jesus Fernandes Fontes and Gecilmara Cristina Salviato Pileggi and Ana L{\'u}cia L Oliveira and Andr{\'e} Machado Siqueira and Danielle Bruna Leal Oliveira and Viviane Fongaro Botosso and Gang Zeng and Qianqian Xin and Mauro M. Teixeira and Maur{\'i}cio Lacerda Nogueira and Esper Georges Kall{\'a}s},
  journal={SSRN Electronic Journal},
  year={2021}
}
Background: Vaccines are urgently needed to tackle the unprecedented morbidity and mortality of COVID-19. Administration of inactivated viruses are the common and mature platform of developing new vaccines. CoronaVac is an inactivated vaccine that has undergone preclinical tests and phase I/II clinical trials. Methods: We conducted a randomised, double-blind, placebo-controlled phase 3 clinical trial with CoronaVac among healthy healthcare professionals in 16 centres in Brazil. Participants… 
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine
TLDR
The immune response before and after SARS-CoV-2 infection was analyzed in nine vaccine breakthrough cases, revealing that six of them exhibited circulating anti-S1-RBD IgG antibodies with neutralizing capacities after immunization, which showed a significant increase 2 and 4 weeks after symptoms onset.
Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial.
TLDR
Both schedules of CoronaVac protected against COVID-19 hospitalizations, especially in over 60 years-old participants, and there were no significant differences for local and systemic AE between schedules.
Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China
TLDR
The findings implied that the inactivated CoronaVac vaccine has an acceptable safety profile among healthcare workers due to the low incidence of self-reported adverse reactions, which may boost public confidence in nationwide mass vaccination campaigns.
Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3
TLDR
The results indicate that two mRNA vaccine doses prevent SARS-COV-2 infection most effectively, but further research is needed due to the high degree of heterogeneity among studies in this sample.
Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study
TLDR
CoronaVac elicited an antibody response in naïve and pre-immune participants, with mild AEs, and this study described CoronaVac post-vaccination reactogenicity and immunogenicity.
Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis
TLDR
All the COVID-19 vaccines that have published the data of phase III clinical trials have excellent efficacy, and the risk of adverse events is acceptable, meanwhile the risk and grade of adverse Events was minimal, compared to that of severe symptoms induced by CO VID-19.
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.
TLDR
The use of CoronaVac in patients with ARD is supported, suggesting reduced but acceptable short-term immunogenicity and the trial is still ongoing to evaluate the long-term effectiveness/immunogenicity.
Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
TLDR
The results of the study indicate that CoronaVac provides protection against COVID-19, and the hospitalization rate was similar in the breakthrough cases and those who had CO VID-19 before CoronaVacs vaccination.
A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease
TLDR
A systematic review of COVID-19 vaccines through February 2022, including efficacy data from Phase 3 clinical trials for 15 vaccines undergoing WHO Emergency Use Listing evaluation and real-world effectiveness for 8 vaccines with observational studies meeting inclusion criteria.
A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease
TLDR
A systematic review of COVID-19 vaccines as of August 2021, which includes efficacy data from Phase 3 clinical trials for 13 vaccines within the WHO Emergency Use Listing evaluation process and real-world effectiveness for 5 vaccines with observational studies meeting inclusion criteria.
...
...